An investigation on behalf of investors in Sorrento Therapeutics Inc (NASDAQ:SRNE) shares over potential wrongdoing at Sorrento Therapeutics was announced and NASDAQ:SRNE stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/13/2016 -- Certain directors of Sorrento Therapeutics Inc are under investigation over potential wrongdoing. The investigation was announced for current investors in NASDAQ:SRNE shares over potential breaches of fiduciary duties by certain officers and directors at Sorrento Therapeutics.
Investors who purchased shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) and currently hold any of those NASDAQ:SRNE shares have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Sorrento Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
Sorrento Therapeutics Inc reported that its annual Total Revenue rose from $0.46 million in 2013 to $4.59 million in 2015 while its Net Loss increased from $21.91 million in 2013 to $45.81 million in 2015.
Shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) declined from as high as $23.51 per share to $4.50 per share in February 2016.
Those who purchased shares of Sorrento Therapeutics Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego